

9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982

Email: info@abeomics.com

12-2003: Anti-IL-23 (Tremfya)(Guselkumab biosimilar) mAb

Clonality: Monoclonal
Application: ELISA
Reactivity: Human
Isotype: IgG1

Description

Tremfya or Guselkumab biosimilar is human immunoglobulin G1 lambda (IgG1lambda) monoclonal antibody, a member of the interleukin inhibitors that selectively block interleukin-23 p19. It usually is important in the treatment of Psoriasis. IL-23 is an inflammatory cytokine responsible for the induction of psoriatic plaque formation. It activates the CD4+ T-helper (Th17) cell pathway. Guselkumab biosimilar developed by Abeomics is for research use only and should not be used in diagnostic procedures.

Product Info

Amount : 100 μg

Purification: Purified from cell culture supernatant by affinity chromatography **Storage condition:** Store at -20°C to -80°C (Avoid repeated freezing and thawing).

Application Note

ELISA 1:5000-10000, FACS 1:100




Fig.1: Coomassie staining of SDS-PAGE gel loaded with Anti-IL-23 (Tremfya)(Guselkumab biosimilar) mAb (Abeomics Cat# 12-2003)